Circulating cardiovascular proteomic associations with genetics and disease

Abstract

Background The analysis of the circulating proteome can identify translational modifiers and biomarkers of disease expressivity and severity at a particular sampling time point. Focused analyses are required to understand the relationships between protein measures of interest and cardiovascular disease and whether they mediate causal relationships between cardiovascular risk factors and disease development.

Methods To understand the relationships between circulating biomarkers and genetic variants, medications, anthropometric traits, lifestyle factors, imaging-derived measures, and diagnoses of cardiovascular disease, we analysed measures of nine plasma proteins with a priori roles in genetic and structural cardiovascular disease or treatment pathways (ACE2, ACTA2, ACTN4, BAG3, BNP, CDKN1A, NOTCH1, NT-proBNP, and TNNI3) from the Pharma Proteomics Project of the UK Biobank cohort (over 45,000 participants sampled at recruitment).

Results We identified significant variability in circulating proteins with age, sex, ancestry, alcohol intake, smoking, and medication intake. Phenome-wide association studies highlighted the range of cardiovascular clinical features with relationships to protein levels. Genome-wide genetic association studies identified variants near GCKR, APOE, and SERPINA1, that modified multiple circulating protein levels (BAG3, CDKN1A, and/or NOTCH1). NT-proBNP and BNP levels associated with variants in BAG3. ACE2 levels were increased with a diagnosis of hypertension or diabetes and were influenced by variants in genes associated with diabetes (HNF1A, HNF4A). Two-sample Mendelian randomisation identified ACE2 as protective for systolic blood pressure and Type-2 diabetes.

Conclusions The results from this observational study provide evidence for ACE2 as a protective biomarker that is increased with a diagnosis of hypertension and diabetes. This suggests that ACE2 stimulation may provide additional protection from these cardiovascular diseases. This study provides an improved understanding of the circulating pathways depicting cardiovascular disease dynamics.

• Download figure
• Open in new tab

Competing Interest Statement

K.A.M. has consulted for Checkpoint Capital LP. D.P.O?R has consulted for Bayer AG and Bristol Myers-Squibb. J.S.W. has consulted for MyoKardia, Inc., Pfizer, Foresite Labs, Health Lumen, and Tenaya Therapeutics, and has received research support from Bristol Myers-Squibb. None of these activities are directly related to the work presented here. All other authors have nothing to disclose.

Funding Statement

K.A.M. is supported by the British Heart Foundation [BHF; FS/IPBSRF/22/27059, RE/18/4/34215]. L.C. is supported by the BHF [RE/18/4/34215]. A.S. is supported by the BHF [FS/CRTF/21/24183] and a National Institute for Health Research (NIHR) Clinical Lectureship. F.S.N. is supported by the BHF [RG/F/22/110078, RE/18/4/34215, RE/24/130023]. J.S.W. is supported by the Sir Jules Thorn Charitable Trust [21JTA], the Medical Research Council (UK) [MC_UP_1605/13], and the BHF [RG/19/6/34387, RE/18/4/34215]. D.P.O is supported by the Medical Research Council [MC_UP_1605/13], and the BHF [RG/19/6/34387, RE/18/4/34215, CH/P/23/80008]. All authors were supported by the National Institute for Health Research (NIHR) Imperial College Biomedical Research Centre. The views expressed in this work are those of the authors and not necessarily those of the funders.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The UK Biobank (UKB) study recruited 500,000 participants aged 40 to 69 years old from across the United Kingdom between 2006 and 2010 (National Research Ethics Service, 11/NW/0382). This study was conducted under the terms of access of projects 47602 and 40616. All participants provided written informed consent.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes